 |
A Canadian Hospital acquires its second 125L Ozone SterilizerSeptember 28, 2007Québec City, September 28 2007 – TSO3 Inc. (“TSO3”) (TOS/TSX) announces the sale of a second 125L Ozone Sterilizer to a Canadian hospital that was among the first to utilize the device. The acquisition of a second ozone sterilizer allows this hospital to completely discontinue the use of Ethylene Oxide within its facility.This hospital is among the most renowned in Cardiology and has achieved numerous firsts, both internationally and within Canada. One can find under the same roof renowned specialists, expertise and leading-edge technology focused in strategic areas such as surgery, hemodynamics, specialized cardiac care, electrophysiology and nuclear medicine. “This hospital provides TSO3 both visibility and credibility with other hospitals specializing in cardiology, since it compares favourably with leading facilities in that field, in the United States as well as in Europe “, said Jocelyn Vézina, CEO for TSO3 Inc. “This second sale to an existing customer is another positive step for TSO3, as it highlights that current users are satisfied with the benefits and advantages of integrating ozone sterilization into their hospitals. Of course, the introduction of a new technology in the medical sector is a long and rigorous process, but the base of satisfied customers that we are currently building will ensure our growth.” About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology whit high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. TSO3 currently has more than 65 employees, about half of whom work in the sales and marketing team. For more information about TSO3, visit the Company’s Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications & IR (418) 651-0003, Ext. 237 Email: ccote@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
